Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of [68Ga]Ga-FAPI-04 in High-Grade Neuroendocrine Neoplasms
NCT07132645Phase 1Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-FAPI-4 in Neuroendocrine Neoplasm (NEN), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Biodistribution of Gallium Ga 68-DOTA-FAPI-04 at Day 1 and Pharmacokinetics of [68Ga] Ga-FAPI-04 at Day 1. Started Sep 2025; status: recruiting.
02
Drugs
68Ga-FAPI-4
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT07132645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132645.